Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, has announced a proposed public offering of its common stock and accompanying warrants. This offering is underwritten, with Guggenheim Securities acting as the sole book-running manager and Newbridge Securities as the co-manager. Genelux plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold.
The offering is backed by an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be filed. The completion of the offering is subject to market conditions and other customary closing conditions.
- Proposed public offering of common stock and warrants can increase capital for Genelux.
- Guggenheim Securities is a reputable institution acting as the sole book-running manager.
- Underwriters have a 30-day option to purchase an additional 15% of shares, showing flexibility.
- Effective shelf registration statement with the SEC provides transparency and compliance.
- Offering may lead to shareholder dilution.
- Uncertainty in completion due to market and other customary closing conditions.
- Potential negative impact on stock price due to market perception of share dilution.
Genelux Corporation's announcement of a proposed public offering of common stock and warrants is an important financial event for the company and its investors. This fundraising effort indicates that Genelux is seeking additional capital, likely to support its ongoing clinical trials and operational needs. Public offerings can dilute existing shareholders' equity, but they also infuse the company with necessary funds to progress its business objectives.
From a financial perspective, the involvement of reputable firms like Guggenheim Securities and Newbridge Securities Corporation adds credibility to this offering. However, investors should be cautious about the potential dilution of shares. The 30-day option to purchase an additional 15% of the shares introduces further uncertainty regarding the final amount of capital raised and the extent of dilution.
Additionally, market conditions and investor sentiment will play a important role in determining the success of this offering. Retail investors should closely monitor the terms of the offering as detailed in the prospectus to evaluate the potential impact on their holdings and the company's balance sheet.
From a market perspective, Genelux Corporation's decision to undertake a public offering of stocks and warrants could be viewed as a strategic move to capitalize on its current market position. Immuno-oncology is a rapidly growing field and additional funds could enable Genelux to accelerate its clinical programs and bring its therapies to market faster.
The timing of the offering suggests confidence in the company's prospects, but it also raises questions about its current cash flow and funding needs. Investors should consider the broader market context, including investor appetite for biotech stocks and general market volatility, as these factors will influence the offering's success.
It is also essential to consider how this move will impact Genelux's competitive positioning. If the offering raises sufficient capital, it could potentially strengthen the company's market standing by enabling further development and scaling of its immuno-oncology treatments.
WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to an additional
Guggenheim Securities is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager for the offering. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares are being offered by Genelux pursuant to an effective shelf registration statement previously filed by Genelux with the U.S. Securities and Exchange Commission (SEC). This offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and may be obtained for free by visiting the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Genelux
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Genelux’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
Forward-Looking Statements
This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the completion, timing and size of the proposed public offering and the expectation to grant the underwriters a 30-day option to purchase additional shares and warrants. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Genelux’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 and in other filings that Genelux makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and Genelux undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
What is Genelux 's proposed public offering?
When did Genelux announce the public offering?
What is the stock symbol for Genelux ?
Who is managing Genelux 's public offering?
What is the underwriters' option in the Genelux offering?
Is the completion of Genelux's offering guaranteed?
